Awake Fiberoptic Intubation
Conditions
Keywords
American Society of Anesthesiologists (ASA), Mallampati Score, Ramsay Sedation Scale (RSS)
Brief summary
The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine versus placebo used for sedation during elective awake fiberoptic intubation.
Detailed description
An awake fiberoptic intubation is indicated for any patient with an anticipated difficult airway because of their anatomy, airway trauma, morbid obesity, or unstable cervical spine injuries. An awake fiberoptic intubation in a non-sedated patient can be extremely stimulating, uncomfortable, and unpleasant. The clinician must focus on maintaining spontaneous breathing, hemodynamic stability, and the patient's comfort. The term awake fiberoptic intubation is used to distinguish this procedure from fiberoptic intubations performed under general anesthesia. Although patients may be sedated for awake fiberoptic intubation, they need to be responsive and capable of maintaining their own airway without assistance. Vital components of a successful awake fiberoptic intubation include an anesthesiologist experienced in this technique, adequate topicalization of the airway, and a sedated yet cooperative subject. Benzodiazepines, combined with opioid, are commonly used for anxiolysis and/or analgesia during awake fiberoptic intubations. Dexmedetomidine has sympatholytic, sedative, analgesic, and anxiolytic effects that attenuate the catecholamine response to perioperative stress. Dexmedetomidine sedates patients by decreasing sympathetic activity and the level of arousal. Further more, dexmedetomidine has been found to facilitate a decrease in salivary secretion, a desirable effect during fiberoptic intubations. An estimated 100 subjects (50 DEX, 50 PBO) scheduled for an elective awake fiberoptic intubation because of a potentially difficult airway will be randomized prior to intubation at approximately 18 investigative sites.
Interventions
DRUGPlacebo
Sponsors
Hospira, now a wholly owned subsidiary of Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adult (≥18 years of age); 2. American Society of Anesthesiologists (ASA) score I - IV inclusive; 3. Male or female. If female, subject is non-lactating and is either: 1. Not of childbearing potential, defined as post-menopausal for at least 1 year or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy or hysterectomy. 2. Of childbearing potential but is not pregnant at time of baseline and is practicing one of the following methods of birth control: oral or parenteral contraceptives, double-barrier method, vasectomized partner, or abstinence from sexual intercourse. 4. Requiring awake fiberoptic (oral or nasal) intubation because of anticipated difficult airway. Subjects must meet at least one of the criteria listed below: Criteria for Assessing Difficult Airways i. History of difficult intubation ii. Anticipated difficult airway 1. Prominent protruding teeth 2. Small mouth opening 3. Narrow mandible 4. Micrognathia 5. Macroglossia 6. Short, muscular neck 7. Very long neck 8. Limited neck extension 9. Congenital airway anomalies 10. Obesity 11. Known airway pathology 12. Known airway malignancy 13. Upper airway obstruction iii. Trauma 1. Face 2. Upper airway 3. Cervical spine iv. Anticipated difficult mask ventilation v. Severe risk of aspiration vi. Respiratory failure vii. Severe hemodynamic instability 5. Subject (or subject's legally authorized representative) must voluntarily sign and date the informed consent.
Exclusion criteria
1. Previous exposure to any experimental drug within 30 days prior to study drug administration; 2. Central nervous system (CNS) disease with an anticipated increased intracranial pressure or cerebrospinal fluid (CSF) leak; 3. Uncontrolled seizure disorder and/or known psychiatric illness that could confound a normal response to sedative treatment; 4. Presence of acute alcohol intoxication; 5. Current (within 14 days of study entry) treatment with an α2-agonist or antagonist; 6. Subject for whom benzodiazepines, dexmedetomidine or other α2-agonists are contraindicated; 7. Subject received an IV or oral (PO) opioid within one hour or intramuscularly within four hours of the start of study drug administration; 8. Subject has acute unstable angina, laboratory confirmed acute myocardial infarction within the past 6 weeks, heart rate \<50 bpm, systolic blood pressure (SBP) \<90 mmHg, or complete heart block unless they have a pacemaker. 9. Subject has elevated serum glutamic pyruvate aminotransferase/alanine transaminase (SGPT/ALT) and/or Serum glutamic oxaloacetic transaminase/ aspartate aminotransferase (SGOT/AST) values of ≥2 times the upper limit of normal (ULN). 10. Subject has any other condition or factor which, in the Investigator's opinion, might increase the risk to the subject.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The percentage of subjects requiring rescue midazolam to achieve and/or maintain proper sedation levels throughout the study drug infusion | At baseline and 15 minutes after starting study drug (prior to topicalization), and every 3 minutes thereafter throughout study drug infusion, at the end of topicalization, and prior to administration of any rescue medication. | Sedation levels (Ramsay Sedation Scale \[RSS\] score ≥2 \[Patient is cooperative, oriented and tranquil\]) |
Secondary
| Measure | Time frame |
|---|---|
| Total dose of rescue midazolam required to achieve and/or maintain target sedation levels | During the drug maintenance (i.e, Approximately 15 minutes after starting study drug). |
| Percentage of subjects requiring additional rescue medications other than midazolam to achieve and/or maintain target sedation levels | During the drug maintenance (i.e, Approximately 15 minutes after starting study drug). |
| Anesthesiologist assessment of ease of subject care | Immediately following discontinuation of study drug, prior to the scheduled surgery/procedure (Approximately 24 hours). |
| Subject recall and satisfaction assessed 24 hours post study drug | At the end of the 24-Hour Follow-Up Period |
Countries
United States
Outcome results
None listed